| INTRODUC TI ON
Irritable bowel syndrome (IBS) is a typical functional gastrointestinal (GI) disorder with a high worldwide prevalence. 1 According to the recent Rome IV criteria, IBS is characterized by persistent or recurrent abdominal pain which is associated with disturbed bowel movements. 2 Four subtypes are defined based on predominant stool consistency: IBS with predominant diarrhea, IBS with predominant constipation (IBS-C), IBS with mixed bowel habits, and IBS unclassified. Quality of life (QOL) is greatly reduced in patients with IBS. 3 Direct and indirect costs of medical care in IBS patients in the US are 1.4 times more than in healthy subjects. 4 Moreover, the costs of IBS and allied functional GI disorders are also substantial for both healthcare systems and society. 5, 6 Therefore, developing effective treatment for IBS is beneficial not only to individual patients but also to countries.
There are subtype-dependent and subtype-independent treatments for IBS, and the initial step is gut directed. 7 The Food and Drug Administration (FDA) in the US 8 and European Medicines Agency (EMA) in the EU 9 have published guidelines for developing pharmacological treatment of IBS. The common strategies for initial IBS treatment are subtype dependent in both sets of guidelines. 8, 9 The Pharmaceuticals and Medical Devices Agency (PMDA) in Japan also reviews new agents for approval for the treatment of IBS. 10, 11 However, there was no approved treatment specific for IBS-C in Japan. In contrast, linaclotide has been developed for patients with IBS-C in the US and the EU. 12, 13 Linaclotide is a 14-amino acid peptide which activates the guanylate cyclase C (GC-C) receptor expressed on the cell membrane of the luminal side of enterocytes. 14, 15 On activation of GC-C, cyclic guanosine monophosphate (cGMP) is produced in the epithelial cells of the gut and released into the extracellular space.
Increased intracellular cGMP causes secretion of chloride and bicarbonate ions along with water into the intestinal lumen. [16] [17] [18] Increased extracellular cGMP acts on the afferent neurons adjacent to the basolateral cell membrane of the enterocytes and inhibits firing of these intestinal nociceptors. 19 Phase 3 studies conducted in North America and evaluated by the FDA and EMA established linaclotide 0.29 mg once per day as a safe and effective dose for patients with IBS-C. [20] [21] [22] It is not always true that the most effective and safe dose is the same across different populations. 23 Differences in genes, diet, microbiota, and psychosocial stress may modify the effect of pharmacological agents for IBS-C. 23 A phase 2 study of linaclotide conducted before this present study in Japan supported the efficacy and safety of 0.5 mg linaclotide (1.7 times the approved dose in North America and Europe). 24 Therefore, clinical testing was performed to confirm the effect of linaclotide 0.5 mg/d for IBS-C patients in Japan. The aim of this study was to verify the hypothesis that the efficacy of linaclotide 0.5 mg is superior to placebo and to show acceptable safety in Japan.
| ME THODS

| Patient population
This study was conducted in Japan from October 2014 to March 2016 at 60 hospitals and clinics with departments of gastroenterology. Male and female outpatients aged 20-79 years were diagnosed as having IBS-C based on the Rome III diagnostic criteria. 25 In brief, patients were eligible if they fulfilled the criteria for the last 3 months with IBS symptom onset at least 6 months prior to diagnosis. Patients had to have recurrent abdominal pain or discomfort for at least 3 days/month in the last 3 months associated with two or more of the following: improvement with defecation, onset associated with a change in frequency of stool, and/or onset associated with a change in form (appearance) of stool. 25 Patients had to have hard or lumpy stools at least 25% of the time, and loose (mushy) or watery stools with fewer than 25% of bowel movements. 25 Organic diseases were excluded by colonoscopy or double-contrast barium enema if these examinations had not been performed within 5 years.
The study protocol was designed in accordance with the Declaration Patients satisfying the inclusion criteria and not meeting any of the exclusion criteria regarding typical IBS-C symptoms during a 2-week bowel habit observation period were enrolled. The weekly mean abdominal pain/discomfort severity score was required to be 2.0 or more, assessed daily on a 5-point ordinate scale (1, none; 2, mild; 3, moderate; 4, severe; and 5, very severe). 24 A SBM was defined as defecation without laxatives, enema, or manual maneuvers. 13 A complete SBM (CSBM) was defined as an SBM associated with a sensation of complete bowel emptying. 8, 13, 20, 21 Weekly mean CSBM frequency was required to be <3 and SBM frequency ≤5. Stool consistency was classified as type 1, separate hard lumps
Key Points
• Linaclotide has been approved in western countries for IBS with constipation (IBS-C) at a dose of 0.29 mg.
• A previous phase II trial in Japan reported that 0.5 mg/d of linaclotide was the most effective dose in IBS-C patients.
• This phase III trial in IBS-C patients in Japan revealed that 0. 
| Study design
This is a phase 3 study with a screening period, 2-week bowel habit observation period, and 52-week treatment period ( Figure 1A ). The Randomization was performed in a 1:1 ratio using a block size of 6 using a web-based randomization system. For all patients, investigators and sponsors blinding was maintained until all observations and evaluations in Part 1 were completed, statistical analysis plans were finalized, and all data had been entered into the database. Visits were scheduled at weeks 2, 4, 8, and 12 (or at discontinuation) in Part 1 to assess treatment efficacy, drug compliance, and occurrence of adverse events. After Part 1, patients meeting transfer criteria (Table S1) (Table S1 ).
All authors had access to the study data and reviewed and approved the final manuscript.
| Data collection
During the bowel habit observation period and treatment period, patients recorded their IBS symptoms every day, using a paper diary at bedtime and at each bowel movement, and subsequently entered the data into an electronic database daily using an interactive voice response system to support daily completion of data entry in the paper diary. This system of evaluating IBS symptoms has been previously reported as reliable and valid. 10, 11 In the 
| Efficacy and safety endpoints
The coprimary endpoints, approved by PMDA, were the responder of the 12 weeks were considered to be overall responders. Weekly responders of SBM were defined as patients with ≥3 SBM and an increase of ≥1 SBM from baseline at each weekly evaluation point and patients who were weekly responders for at least 6 of the 12 weeks were considered to be overall responders.
As ad hoc additional endpoints, weekly responders of CSBM + 1 and abdominal pain/discomfort severity score were defined as patients with an increase of ≥1 CSBM and decrease in abdominal/discomfort of ≥30% from baseline at each weekly evaluation point, respectively. Patients who were weekly responders for these endpoints for at least 6 of the 12 weeks were considered to be overall responders, with reference to the primary endpoints recommended by FDA guidelines. 8 The composite responder rate was the proportion of patients who had a composite response of both CSBM + 1 and the abdominal pain/ discomfort severity score, with reference to the composite responder definition recommended by FDA guidelines. 8 The median time to first CSBM or SBM was calculated as the time from the initial administration of the first dose of the study drug to the first CSBM or SBM. In addition, the proportions of patients with first CSBM or SBM at 6, 12, 18, 24, 30, 36, 42, and 48 hours after the first dose were assessed.
All adverse events were recorded during the treatment period.
| Statistical analysis
Statistical analysis was performed using SAS Drug Development (ver. 3.4, SAS ver. 9.1.3 and ver. 4.5, SAS ver. 9.4) (SAS Institute Inc., Cary, NC, USA). Sample sizes estimated to provide more than 90%
power to detect differences in both coprimary endpoints between placebo and linaclotide 0.5 mg were based on the phase II clinical study data, 24 using asymptotic normal approximation with a twosided significance level of 0.05. In total, 480 patients (240 patients in each group) were selected for randomization.
Efficacy analyses were performed on the full analysis set, which was as complete as possible and as close as possible to the intention-to-treat (ITT) ideal of including all randomized subjects. 29 The full analysis set included all patients who received at least one dose of the study drug during the treatment period and in whom ≥1 endpoint could be evaluated. To determine the robustness of the results, primary analyses were performed according to the per-protocol set.
Safety analyses were performed for all patients who received at least one dose of the study drug during the treatment period.
Responder rates for the coprimary endpoints are expressed as a percentage of patients, and 95% confidence intervals (95% CIs) are presented. The treatment groups were compared using
Fisher's exact test with a two-sided significance level of 0.05 for each coprimary endpoint. Other responder rate parameters and percentages of subjects with CSBM or SBM within 24 hours after start of the initial administration of the study drug were similarly analyzed. To compare the linaclotide groups with placebo, analysis of covariance for change from baseline endpoints was performed with the treatment groups as a factor and baselines as covariates (weekly mean CSBM frequency, weekly mean SBM frequency, weekly mean stool form score, straining severity score, abdominal pain/discomfort severity score, abdominal bloating severity score, and the overall IBS-QOL and IBS-QOL subscale scores). In Part 2, overall IBS-QOL and subscale IBS-QOL scores obtained at baseline and at weeks 24 and 52 were compared to baseline using a paired t test. The median time to first CSBM or SBM was compared using the Kaplan-Meier method and log-rank test. Cumulative incidences of CSBM or SBM at specified time points after start of the initial administration were estimated by the Kaplan-Meier method.
| RE SULTS
| Overall study population
Of the 1008 patients who provided written informed consent, 508 patients were excluded following the screening period and 500 pa- 
| Primary endpoint
The responder rate of the global assessment of relief of IBS symptoms during 12 weeks in the linaclotide group (33.7%, 95% CI 27.9-40.0) was significantly higher than that in the placebo group (17.5%, 95% CI 13.0-22.8, Fisher's exact test, P < 0.001) (Figure 2A ). and a NNT of 7 (95% CI 5-13). (Table S3 ).
| Other endpoints in part 1
The responder rate of abdominal pain/discomfort relief during (Table S3 ).
The composite responder rates of CSBM + 1 and the abdominal pain/discomfort severity score during 12 weeks in the linaclotide group (19.7%, 95% CI 14.9-25.2) was also significantly higher than that in the placebo group (10.0%, 95% CI 6.5-14.4, Fisher's exact test, P = 0.002) ( Figure 3D ). The difference between the linaclotide and placebo groups for composite responder rates of CSBM + 1 and abdominal pain/discomfort responder was 9.7% (95% CI 3.1-16.3) with a RR of 1.98 (95% CI 1.26-3.09) and a NNT of 11 (95% CI 7-32) ( Table S3 ). The IBS-QOL overall score was significantly better for linaclotide compared with placebo at week 4 (P = 0.022), and numerically better, but not significant, at week 8, week 12, and the last evaluation ( Figure S1 ). At the last evaluation time point, linaclotide performed significantly better on the subscale for body image (P = 0.002) and social reaction (P = 0.040) of the IBS-QOL compared to placebo, but not for the other subscales of the IBS-Q OL ( Figure S1 ). The linaclotide group also showed significantly better efficacy for other secondary endpoints compared to the placebo group ( Figures S1 and S2 ).
| Efficacy endpoints in part 2
In 
| Safety in part 1
Safety in Part 1 was evaluated in 500 patients. Adverse events were observed in 65 patients (25.9%) in the placebo group and 78 patients (31.3%) in the linaclotide group. The incidence of diarrhea was higher in the linaclotide group than that in the placebo group (9.6% vs 0.4%, Fisher's exact test, P < 0.001) ( Table 2 ). All occurrences of diarrhea in Part 1 were mild or moderate. Drug-related serious adverse events included asthenic conditions (one patient) in the linaclotide group and white blood cell count decreased (one patient) in the placebo group.
The magnitude of adverse events based on relative risks and numbers needed to harm was shown in Table S3 .
| Safety in part 2
Safety in Part 2 was evaluated in 324 patients. Adverse events were observed in 81 patients (50.6%) in the placebo-linaclotide 
| D ISCUSS I ON
The results of this study support the hypothesis that the efficacy of linaclotide 0.5 mg is superior to that of placebo with an acceptable safety profile in patients in Japan. In the phase 2 study, which was conducted prior to this study, we identified linaclotide 0.5 mg as the appropriate dose to treat IBS-C patients in Japan. 24 Therefore, this study replicated the finding that linaclotide 0.5 mg is effective and tolerable for IBS-C patients in Japan. This dose finding is in contrast with the previous phase 2 13 and phase 3 20, 21 studies in the US. In those studies, linaclotide 0.29 mg was the best dose for IBS-C patients in the US. For patients with chronic constipation in the US, 0.145 mg linaclotide was proven to be effective. 30 The FDA approved the 0.29 mg dose for IBS-C and both the 0.145 mg dose 31 and the 0.072 mg dose 32 for chronic constipation. Moreover, the NNT using the FDA composite responder in this study was 11 [7, 32] , which is higher than that in the phase 3 studies for IBS-C conducted in the US ( Several factors may be responsible for the higher dose requirement for linaclotide in the Japanese population. The GC-C receptor located on the apical membrane of the epithelial cells of the gut is activated by GC-C ligand. 14, 15 This results in an increase in intracellular cGMP in the epithelial cells of the gut which leads to increased secretion of chloride and bicarbonate ions into the gut lumen with a concomitant increase in the secretion of water. [16] [17] [18] 33 Differences in genetic polymorphisms of these pathways between Japanese and US citizens, such as a GUCY2C gene (encoding GC-C), 34 may be one of these factors. Guanylin and uroguanylin belong to the guanylinfamily hormones which are synthesized in the intestine and released both luminally and into the circulation and work on the endogenous ligand of the GC-C receptor. 34 Japanese patients may have more F I G U R E 5 Efficacy endpoints to support long-term efficacy of linaclotide. Symbol height: responder rate (%). Error bar: 95% CI. In the Figure 5C , P values derived by paired t test compared to baseline. A, Weekly responder rate of global assessment of relief of IBS symptoms; B, Weekly responder rate of CSBM; C, IBS-QOL-J score in Part 2
intraluminal guanylin which competitively binds to the GC-C receptors than US or European patients. Also, there is a 10-to 100-fold interindividual variability in GC-C mRNA expression in normal intestinal epithelial cells across the population. 35 Therefore, individual factors including genetic polymorphism may be the origin of dose effect differences between North America and Japan.
The Japanese have different gut microbiota from those in Western countries. 36 Porphyranases and agarases which were from dietary microbiota are common in the Japanese population, and are absent in North American individuals. 37 Linaclotide is converted to the metabolite MM-419447 in the small intestine. 34 The disulfide bonds of both peptides are cleaved, proteolyzed, and degraded in the small intestine. 34 When compared with other nations, 36 the Japanese also have more abundant Bifidobacteria which have exopeptidases. 38 A difference in endogenous or bacterial proteases may thus explain why a dose of 0.5 mg/d is more appropriate for IBS-C patients in Japan.
The Japanese have a different diet from people in Western countries. 23 They consume less dietary fat (http://www.mhlw.go.jp/ bunya/kenkou/kenkou_eiyou_ chousa.html) than Americans (https:// www.ars.usda.gov/northeast-area/beltsville-md/beltsville-human-nutrition-research-center/food-surveys-research-group/ docs/wweia-data-tables/). Obesity due to overeating produces less guanylin expression in the colon with subsequent GUCY2C silencing. 39 The Japanese diet may induce more expression of intraluminal guanylin than a Western diet, which may dampen the effect of linaclotide. 34 In this study, the responder rates of global improvement and CSBM were the primary endpoints. In addition, the responder rate of abdominal pain/discomfort severity score during 12 weeks was an important endpoint. This endpoint along with the responder rate of CSBM + 1 are coprimary endpoints for IBS-C clinical trials recommended by the FDA guidelines. 8 In contrast, the responder rate of global assessment of relief of IBS symptoms during 12 weeks has been approved as a primary endpoint for clinical trials by the Japanese PMDA, 10, 11, 24 and is in accordance with the Rome IV recommendations. 23 Therefore, although the primary endpoints in this study are not identical to those in recent studies in the US, 13, 20, 21 the primary outcome measures in this study do incorporate elements of the FDA guidelines. 8 We also found that linaclotide induced CSBM and SBM within 6 hours after initial administration in 14.9% and 38.2% of patients, respectively, followed by gradual onset of first CSBM/SBM across the rest of the study population. Interestingly, this pattern of TA B L E 2 Incidence of adverse events (≥2% in each part) Data are expressed as "number (%)". Events with an incidence of ≥2% in the placebo group or the linaclotide group in Part 1, and those in the placebo→linaclotide group or the linaclotide→linaclotide group in Part 2 are all listed. P values were calculated using Fisher's exact test.
response was also seen in the placebo-treated patients (2.4% and 15.5% in the first 6 hours), albeit at lower incidences compared to linaclotide-treated patients. To our knowledge, this study is the first to report on a differential time course to first CSBM and SBM after the administration of agents for IBS-C. 13, [20] [21] [22] [30] [31] [32] Long-term administration of linaclotide in Part 2 of this study Additionally, despite lacking a placebo-control group, improvement in the IBS-QOL was seen at the end of long-term treatment with linaclotide. QOL in IBS can be improved in patients by pharmacotherapy using a longer duration of therapy and/or a larger sample size. 3 Secondly, the primary endpoint of this study was not exactly the same as that in the FDA guidelines 8 or the EMA guidelines for IBS treatment, 9 but these endpoints were included as secondary and ad hoc additional endpoints in the Japanese trial. In addition, the primary endpoints in this trial were approved by the PMDA in Japan. Given that regional guidelines for IBS endpoints differ, our primary endpoints are not necessarily a limitation of the study. In fact, this study is a good example of pharmacotherapy development being based on consideration of multicultural differences among countries. 23 In conclusion, this study clearly showed evidence that linaclotide can be clinically applicable outside the US. Results of this phase 3 study suggest that 0.5 mg of linaclotide is effective and safe for IBS-C patients in Japan.
